Skip to content

Author

Naoki Takahashi

We have 2 of 36 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.

BACKGROUND The prognostic significance of PD-L1 expression in unresectable/recurrent gastric cancer treated by first-line chemotherapy without an immune checkpoint inhibitor (ICI) remains unclear. The phase III trial JCOG1013 demonstrated no overall survival (OS) or progression-free survival (PFS) benefit of docetaxel/...

H. Hirano, Yasuhide Yamada, Kengo Nagashima et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.